InflaRX set to file for MAA for vilobelima...InflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients. more ➔
New Amsterdam Pharma merges with Frazier L...Through a $325m SPAC transaction with Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Holding B.V. will go public on Nasdaq. The newly formed holding company, NewAmsterdam Pharma Company … more ➔
New antibody cocktail might fight all coro...A nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic. more ➔
French-German Novasep-PharmaZell Group inv... This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) … more ➔
impact, innovation, investment, Oxford, techtransfer, translation, TTO Oxford Science Enterprises raised a furthe... Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced … more ➔
Swedish Bioinvent issues shares worth SEK2... BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including … more ➔
Immunocore has a sip with USD140m private...Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline. more ➔
biotech, consumer health, GSK, Haleon, IPO, listing, London, pharma, split, stock exchange GSK splits off consumer health as Haleon &... GlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK … more ➔
Polpharma Biologics Announces EMA Acceptan... European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS). more ➔
Agomab extenses Series B with USD40m Bring... Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount … more ➔